Provided by Tiger Fintech (Singapore) Pte. Ltd.

AbCellera Biologics

2.52
+0.12005.00%
Post-market: 2.50-0.0207-0.82%19:59 EDT
Volume:4.45M
Turnover:11.23M
Market Cap:750.93M
PE:-4.55
High:2.60
Open:2.45
Low:2.45
Close:2.40
Loading ...

AbCellera Biologics (ABCL) Gets a Buy from Truist Financial

TIPRANKS
·
03 Mar

AbCellera Biologics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
01 Mar

AbCellera Biologics’ Earnings Call: Transition Amid Challenges

TIPRANKS
·
01 Mar

Stock Track | AbCellera Stock Plummets 16.78% in Pre-Market After Wider 2024 Loss Despite Pipeline Progress

Stock Track
·
28 Feb

Stock Track | AbCellera Stock Plunges 5.8% Pre-Market on Wider 2024 Loss Despite Pipeline Progress

Stock Track
·
28 Feb

AbCellera Biologics Inc (ABCL) Q4 2024 Earnings Call Highlights: Strategic Shifts Amid ...

GuruFocus.com
·
28 Feb

AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
28 Feb

Abcellera Biologics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

TD Cowen Keeps Their Buy Rating on AbCellera Biologics (ABCL)

TIPRANKS
·
28 Feb

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
28 Feb

BRIEF-AbCellera Biologics Files For Mixed Shelf, Size Not Disclosed - SEC Filing

Reuters
·
28 Feb

AbCellera files automatic mixed securities shelf

TIPRANKS
·
28 Feb

Abcellera Biologics Inc Files for Mixed Shelf ; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
28 Feb

AbCellera Biologics Q4 GAAP EPS $(0.12) Beats $(0.15) Estimate, Sales $5.10M Miss $7.58M Estimate

Benzinga
·
28 Feb

AbCellera Biologics Reports 2024 Financial Results and Growth

TIPRANKS
·
28 Feb

BRIEF-AbCellera Q4 Revenue USD 5.1 Million Vs. IBES Estimate USD 7.58 Million

Reuters
·
28 Feb